A clinical-stage rare disease biotech formed by Actio Biosciences alums
setarabiosciences.comSan DiegoBiotech
45 sources · checked 1 time, last 1d ago
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A | $90M | 2026-10-30 | not stated | No recent discussion |
45 sources · checked 1 time, last 1d ago [ VERIFIED · CORRECTED ] read against 4 of 45 sources
[ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]45 pages read: setarabiosciences.com, businesswire.com, amp.axios.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 4 of 45 sources·[ AGENT ]company research by the Firecrawl agent | ||||
Setara develops small-molecule precision medicines for severe rare diseases by using genetic insights to target the underlying causes of disease, while applying those insights to broader conditions.
CMT2C is a severe inherited disease with no approved therapies and only supportive care, while overactive bladder affects tens of millions of people and current treatments have limited efficacy. Setara's $90 million Series A is funding STAR-0871, which has completed the healthy-volunteer portion of Phase 1 and is planned for a 2027 Phase 1b CMT2C study and a parallel Phase 2a overactive-bladder study, alongside earlier discovery programs.